Holen Sie sich die Stockscreener-App
7.12
2.01%
0.14
Handel nachbörslich:
7.12
Schlusskurs vom Vortag:
$6.98
Offen:
$7
24-Stunden-Volumen:
45,956
Relative Volume:
0.42
Marktkapitalisierung:
$35.53M
Einnahmen:
$34.77M
Nettoeinkommen (Verlust:
$-74.04M
KGV:
-0.9013
EPS:
-7.9
Netto-Cashflow:
$-79.76M
1W Leistung:
-7.05%
1M Leistung:
+3.79%
6M Leistung:
-43.97%
1J Leistung:
-80.22%
1-Tages-Spanne:
$6.80
$7.16
1-Wochen-Bereich:
$6.80
$7.85
52-Wochen-Spanne:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
7.12 | 35.03M | 34.77M | -74.04M | -79.76M | -7.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
What does recent volatility data suggest for Mersana Therapeutics Inc. - Newser
How sensitive is Mersana Therapeutics Inc. to inflation2025 Winners & Losers & AI Powered Trade Plan Recommendations - khodrobank.com
How volatile is Mersana Therapeutics Inc. stockWeekly Trade Report & Long Hold Capital Preservation Tips - khodrobank.com
Will Mersana Therapeutics Inc. face regulatory challengesJuly 2025 Drop Watch & Reliable Breakout Stock Forecasts - khodrobank.com
Using Bollinger Bands to evaluate Mersana Therapeutics Inc.Profit Target & AI Enhanced Trading Alerts - Newser
Can Mersana Therapeutics Inc. stock double in the next yearJuly 2025 WrapUp & High Accuracy Swing Trade Signals - khodrobank.com
Is Mersana Therapeutics Inc. stock reversal real or fakeMarket Performance Summary & Proven Capital Preservation Tips - Newser
Is Mersana Therapeutics Inc. a top pick in the sectorDividend Hike & Weekly Market Pulse Updates - khodrobank.com
Best data tools to analyze Mersana Therapeutics Inc. stockMarket Volume Summary & Low Risk Entry Point Guides - Newser
Is Mersana Therapeutics Inc. reversing from oversold territoryEarnings Summary Report & Breakout Confirmation Alerts - Newser
Evaluating Mersana Therapeutics Inc. with trendline analysisRisk Management & Risk Managed Trade Strategies - Newser
Mersana Therapeutics Inc. recovery potential after sell offJuly 2025 PreEarnings & Verified Swing Trading Watchlists - Newser
Leading vs lagging indicators on Mersana Therapeutics Inc. performanceJuly 2025 Analyst Calls & Weekly High Momentum Picks - Newser
Analyzing net buyer seller activity in Mersana Therapeutics Inc.July 2025 Technicals & Verified Momentum Stock Alerts - Newser
What recovery options are there for Mersana Therapeutics Inc.2025 Technical Overview & Verified Trade Idea Suggestions - Newser
Will Mersana Therapeutics Inc. bounce back from current support2025 Technical Overview & Accurate Intraday Trade Tips - Newser
How moving averages guide Mersana Therapeutics Inc. tradingWeekly Stock Report & Risk Controlled Swing Alerts - Newser
Using Python tools to backtest Mersana Therapeutics Inc. strategiesAnalyst Upgrade & Weekly Return Optimization Plans - Newser
Using data tools to time your Mersana Therapeutics Inc. exitQuarterly Trade Review & Reliable Entry Point Alerts - Newser
Has Mersana Therapeutics Inc. formed a bullish divergenceEarnings Growth Summary & Verified Stock Trade Ideas - Newser
Can Mersana Therapeutics Inc. generate free cash flowJuly 2025 Summary & Consistent Return Strategy Ideas - khodrobank.com
Sector ETF performance correlation with Mersana Therapeutics Inc.Options Play & High Win Rate Trade Tips - Newser
What Fibonacci levels say about Mersana Therapeutics Inc. reboundJuly 2025 Closing Moves & High Yield Stock Recommendations - Newser
Can momentum traders help lift Mersana Therapeutics Inc.2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - Newser
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsWeekly Trend Report & Weekly Setup with ROI Potential - Newser
Key resistance and support levels for Mersana Therapeutics Inc.Earnings Risk Report & Technical Confirmation Alerts - Newser
How sentiment analysis helps forecast Mersana Therapeutics Inc.2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
Chart based exit strategy for Mersana Therapeutics Inc.2025 Market Outlook & Real-Time Buy Zone Alerts - Newser
Is Mersana Therapeutics Inc. stock forming a cup and handleJuly 2025 Technicals & Reliable Entry Point Alerts - khodrobank.com
Is now a turning point for Mersana Therapeutics Inc.Trade Exit Summary & High Return Trade Opportunity Guides - Newser
Signal strength of Mersana Therapeutics Inc. stock in tech scannersJuly 2025 Summary & Free Safe Entry Trade Signal Reports - Newser
What’s the beta of Mersana Therapeutics Inc. stockJuly 2025 Price Swings & Stepwise Swing Trade Plans - khodrobank.com
Can Mersana Therapeutics Inc. reach resistance levels soon2025 Technical Patterns & Real-Time Volume Analysis - khodrobank.com
Is Mersana Therapeutics Inc. subject to activist investor interestAnalyst Downgrade & Weekly Momentum Picks - khodrobank.com
How does Mersana Therapeutics Inc. perform in inflationary periods2025 Key Lessons & Daily Price Action Insights - خودرو بانک
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionWeekly Gains Report & Reliable Intraday Trade Plans - Newser
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mersana Therapeutics Inc-Aktie (MRSN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
| Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):